Most importantly we demonstrate that in an orthotopic xenograft model of the most aggressive c-myc-amplified human medulloblastoma variant GDC-0941 adminstration result in tumor growth delay and survival benefit underscoring the potential of PI3K-inhibition for medulloblastoma therapy. The gene discussed is MYC; the disease is neoplasm.